"It's been a long road with many failures, and it shows the importance of basic research - you just keep putting one foot in front of the other, and then suddenly you have something." Brunger and Dickey have filed a joint provisional patent application with Stanford's Office of Technology Licensing and the MD Anderson Cancer Center's Office of Technology Commercialization
Few studies exist evaluating GHK-Cu for alopecia and so specific studies on effective concentration for this indication are unavailable, anecdotally some compounders use 0.2-3%
IV therapy delivers fluids, electrolytes, minerals, and vitamins that help replenish your body
This information is provided for educational purposes to support informed research decisions.
GHK-Cu Peptide is intended for research and educational purposes only
Most medspa-style content cites general statements about nasal drug delivery without acknowledging the size cutoff that makes BPC-157 a poor candidate without enhancers